

**Luminex**  
complexity simplified.



Reimagine your discoveries  
Amnis<sup>®</sup> ImageStream<sup>®</sup> Mk II and  
FlowSight<sup>®</sup> Imaging Flow Cytometers

Learn more >



## Single Amino Acid Replacements in an Antigenic Peptide Are Sufficient to Alter the TCR V $\beta$ Repertoire of the Responding CD8<sup>+</sup> Cytotoxic Lymphocyte Population

This information is current as of June 13, 2021.

Alexis M. Kalergis, Toshiro Ono, Fuming Wang, Teresa P. DiLorenzo, Shinichiro Honda and Stanley G. Nathenson

*J Immunol* 1999; 162:7263-7270; ;  
<http://www.jimmunol.org/content/162/12/7263>

**References** This article **cites 41 articles**, 17 of which you can access for free at:  
<http://www.jimmunol.org/content/162/12/7263.full#ref-list-1>

**Why *The JI*? Submit online.**

- **Rapid Reviews! 30 days\*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*\*average*

**Subscription** Information about subscribing to *The Journal of Immunology* is online at:  
<http://jimmunol.org/subscription>

**Permissions** Submit copyright permission requests at:  
<http://www.aai.org/About/Publications/JI/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://jimmunol.org/alerts>

*The Journal of Immunology* is published twice each month by  
The American Association of Immunologists, Inc.,  
1451 Rockville Pike, Suite 650, Rockville, MD 20852  
Copyright © 1999 by The American Association of  
Immunologists All rights reserved.  
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



# Single Amino Acid Replacements in an Antigenic Peptide Are Sufficient to Alter the TCR V $\beta$ Repertoire of the Responding CD8<sup>+</sup> Cytotoxic Lymphocyte Population<sup>1</sup>

Alexis M. Kalergis,\* Toshiro Ono,<sup>2\*</sup> Fuming Wang,<sup>3†</sup> Teresa P. DiLorenzo,\* Shinichiro Honda,\* and Stanley G. Nathenson<sup>4\*†</sup>

Cytotoxic CD8<sup>+</sup> T lymphocytes are activated upon the engagement of their Ag-specific receptors by MHC class I molecules loaded with peptides 8–11 amino acids long. T cell responses triggered by certain antigenic peptides are restricted to a limited number of TCR V $\beta$  elements. The precise role of the peptide in causing this restricted TCR V $\beta$  expansion in vivo remains unclear. To address this issue, we immunized C57BL/6 mice with the immunodominant peptide of the vesicular stomatitis virus (VSV) and several peptide variants carrying single substitutions at TCR-contact residues. We observed the expansion of a limited set of TCR V $\beta$  elements responding to each peptide variant. To focus our analysis solely on the TCR  $\beta$ -chain, we created a transgenic mouse expressing exclusively the TCR  $\alpha$ -chain from a VSV peptide-specific CD8<sup>+</sup> T cell clone. These mice showed an even more restricted TCR V $\beta$  usage consequent to peptide immunization. However, in both C57BL/6 and TCR $\alpha$  transgenic mice, single amino acid replacements in TCR-contact residues of the VSV peptide could alter the TCR V $\beta$  usage of the responding CD8<sup>+</sup> T lymphocytes. These results provide in vivo evidence for an interaction between the antigenic peptide and the germline-encoded complementarity-determining region- $\beta$  loops that can influence the selection of the responding TCR repertoire. Furthermore, only replacements at residues near the C terminus of the peptide were able to alter the TCR V $\beta$  usage, which is consistent with the notion that the TCR  $\beta$ -chain interacts in vivo preferentially with this region of the MHC/peptide complex. *The Journal of Immunology*, 1999, 162: 7263–7270.

Cytotoxic CD8<sup>+</sup> T lymphocytes (CTL) play an important role in the cellular immune response to virus infections (1, 2). These T lymphocytes recognize Ags as peptides of 8–11 amino acids bound to MHC class I molecules on the surface of infected cells (3). The MHC class I/peptide complex is the ligand for the TCR, a heterodimeric protein consisting of covalently bound  $\alpha$ - and  $\beta$ -chains (4, 5). The variable regions of the TCR  $\alpha$ - and  $\beta$ -chains are encoded by V/J and V/D/J transcriptional elements, respectively (4, 5). These genetic elements are rearranged as a result of somatic recombination in the thymus during early steps of T cell ontogeny (5).

As is found for Abs, the portions of the TCR variable region predicted to interact with the Ag have been called complementarity-determining regions (CDRs)<sup>5</sup> (5, 6). While the CDR1 and CDR2 are germline encoded by each variable gene segment, the

CDR3 results from the V(D)J junction. Since the CDR3 shows the highest diversity within the TCR structure, it was initially proposed that this portion of the TCR would interact with the antigenic peptide, while the less diverse CDR1 and CDR2 would contact the MHC  $\alpha$ -helices (7). However, the recently solved crystal structures of three MHC class I-restricted TCRs complexed with their cognate ligands have revealed that in addition to the CDR3, the CDR1 could also interact with the peptide (8–11). In these structures, the CDR3 of the  $\alpha$ - and  $\beta$ -chains come in close apposition, interfacing the center of the peptide, while the CDR1 of the  $\alpha$ - and  $\beta$ -chains contact residues of the antigenic peptide near the N and C termini, respectively (8–11). It is interesting that all the structures show the same overall orientation, in which the TCR interfaces the MHC class I/peptide complex in a diagonal orientation parallel to the  $\beta$  sheets of the MHC Ag binding groove, with the  $\alpha$ - and  $\beta$ -chains flanking the amino and carboxyl termini of the peptide, respectively (8–12). This diagonal orientation revealed by the crystal structures agrees with that previously predicted by in vivo studies performed with CTL clones and transgenic mice (13, 14).

However, despite structural and biochemical data addressing the role that the different regions of the TCR play in the interaction with the MHC/peptide complex, still largely unknown are the structural features that determine which members of the highly diverse TCR repertoire are expanded during the onset of a T cell response triggered by a particular Ag. In this regard, it has been observed in a variety of systems that the T cell response to an Ag is biased toward the usage of a limited set of TCR variable gene families (15–18). These observations have revealed that the T cell responses are preferentially oligoclonal, involving the activation of a restricted set of T cell clones (17). This oligoclonality is presumably determined by the structure of the antigenic peptide and its interaction with the responding TCR molecules.

Departments of \*Microbiology and Immunology and <sup>†</sup>Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.

Received for publication January 21, 1999. Accepted for publication March 29, 1999.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by National Institutes of Health Grants RO1 AI07289-32, 5T52CA09173-23, and RO1 AR42533-5. T.P.D. is a fellow of the Cancer Research Institute.

<sup>2</sup> Current address: Department of Parasitology and Immunology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700, Japan.

<sup>3</sup> Current address: Corixa Corporation, 1124 Columbia Street, Suite 225, Seattle, WA 98104.

<sup>4</sup> Address correspondence and reprint requests to: Dr. Stanley G. Nathenson, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461. E-mail address: nathenso@aecom.yu.edu

<sup>5</sup> Abbreviations used in this paper: CDR, complementarity-determining region; VSV, vesicular stomatitis virus; B6, C57BL/6;  $\beta_2m$ ,  $\beta_2$ -microglobulin.

To study the role that the structure of the antigenic peptide plays in the expansion of the responding T cells during an immune response, we analyzed the effect that single amino acid replacements in the sequence of an antigenic peptide have on the repertoire of activated T cells. As a system, we have used an eight-amino acid-long peptide corresponding to residues 52–59 from the nucleocapsid of the vesicular stomatitis virus (VSV) (19). The VSV peptide binds to H-2K<sup>b</sup>, triggering a strong immune response mediated by cytotoxic CD8<sup>+</sup> T cells. Previous analysis of VSV-specific CTL clones revealed the preferential usage of the V $\beta$ 13 and V $\beta$ 8 elements (20). Functional studies and analysis of the crystal structure of the H-2K<sup>b</sup>/VSV complex have allowed the potential TCR-contact residues of the VSV peptide to be identified (21–23). In the present work, we asked how single amino acid replacements in TCR-exposed positions of the VSV peptide would affect the TCR repertoire of the responding CD8<sup>+</sup> T cell population.

When C57BL/6 (B6) mice were immunized with the VSV peptide, the predominant TCR V $\beta$  element used by the responding CD8<sup>+</sup> T cell population was V $\beta$ 13. Immunization of these mice with certain singly substituted VSV-derived peptide variants caused a change in the predominant TCR V $\beta$  usage. To focus our study on changes in the TCR  $\beta$ -chain resulting from alterations in the sequence of the VSV peptide independently of the TCR  $\alpha$ -chain, we created a transgenic mouse that expressed exclusively the TCR  $\alpha$ -chain of a VSV-specific, H-2K<sup>b</sup>-restricted T cell clone (N30.7, V $\alpha$ 2/V $\beta$ 13) (20, 24). When the transgenic mice were immunized with the VSV peptide, V $\beta$ 13 was again the predominant V $\beta$  element present in VSV-specific CTL populations. However, the TCR V $\beta$  usage was profoundly altered when these transgenic mice were immunized with peptides carrying single replacements near the C terminus of VSV. Peptides with replacements at the N terminus of VSV were able to induce a strong cytotoxic response but did not alter the TCR V $\beta$  usage. Our results are discussed with regard to the orientation of the TCR/ligand interaction *in vivo* and the effects that point mutations in the epitope sequence can have on the nature of responding cytotoxic T cells.

## Materials and Methods

### Peptide synthesis and purification

The wild-type VSV peptide (RGYVYQGL) and singly substituted variants were synthesized by a solid-phase method using Fmoc chemistry on an automated 433A peptide synthesizer (Applied Biosystems, Foster City, CA) at the Peptide Synthesis Facility of the Albert Einstein College of Medicine. All peptides were purified to >98% homogeneity by reversed-phase HPLC on a Vydac C-18 column (2.1 or 4.6 mm  $\times$  25 cm, 300 Å) using HP-1090M HPLC (Hewlett Packard). The identity of the purified peptides was determined by a tandem quadrupole mass spectrometer (TSQ700, Finnigan MAT, San Jose, CA).

### Animals and immunizations

B6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The N30.7 V $\alpha$ 2 transgenic mice were designed as described previously by Wang et al. (24). These mice carry the TCR  $\alpha$ -chain of the H-2K<sup>b</sup>/VSV-specific CTL clone N30.7 (20) as a transgene in a TCR $\alpha$ <sup>-/-</sup> background. All animals were maintained under approved institutional guidelines in the Animal Institute of the Albert Einstein College of Medicine.

Mice were immunized by injecting 15  $\mu$ g of peptide emulsified in CFA in the hind footpads. Seven days later, animals were boosted with 15  $\mu$ g of peptide emulsified in IFA. One week after the booster, animals were sacrificed and spleens removed for culture and generation of peptide-specific CTL populations.

### Culture of peptide-specific CTL populations and cytotoxicity assays

Splenic cells ( $5 \times 10^7$ ) were cultured for 7 days in 10 ml of IMDM, supplemented with 2 mM glutamine, 50 U/ml penicillin, 50  $\mu$ g/ml streptomycin, 50  $\mu$ M 2-ME, and 10% heat-inactivated FCS (HyClone, Logan, UT), in the presence of 1  $\mu$ M of the peptide used for immunization. At day

7, cells were restimulated with the same peptide (1  $\mu$ M) presented by mitomycin C-treated syngeneic B6 splenic cells. Cultures were supplemented with 50 U/ml rhIL-2. At day 14 of culture, cells were harvested for cytotoxic assays and V $\beta$  family usage analyses. This protocol was followed for generation of peptide-specific CTL populations from both wild-type B6 and N30.7 V $\alpha$ 2 transgenic mice.

Peptide-specific cytotoxicity mediated by CTL populations was determined by <sup>51</sup>Cr release assay. RMA/s cells were incubated for 1 h at 37°C with 1.85 MBq of Na<sub>2</sub><sup>51</sup>CrO<sub>4</sub> and 1  $\mu$ M of specific peptide. These target cells ( $3 \times 10^3$ ) were mixed with CTL effector cells in E:T ratios ranging from 30 to 50. After a 4-h incubation at 37°C and 8% CO<sub>2</sub> in air, supernatants were collected and the amount of <sup>51</sup>Cr released was measured in a gamma counter. The percentage of specific lysis was determined as  $100 \times (\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})$ . Experimental release is the radioactivity in the supernatant of target cells mixed with CTLs, spontaneous release is that in the supernatant of target cells incubated alone, and maximum release is that in the supernatant after complete lysis of target cells with 1% Triton X-100 in PBS.

### Preparation of the H-2K<sup>b</sup>/VSV tetramers and binding to VSV-specific CD8<sup>+</sup> CTL populations

The detailed procedure for preparation and characterization of H-2K<sup>b</sup>/VSV tetramers will be described elsewhere (A. M. Kalergis, E. Palmieri, E. C. Goyarts, S. Honda, and S. G. Nathanson, manuscript in preparation). Briefly, using a form of the H-2K<sup>b</sup> molecule carrying a single unpaired cysteine residue at the C terminus, H-2K<sup>b</sup>/ $\beta$ <sub>2m</sub>-microglobulin ( $\beta$ <sub>2m</sub>)/VSV complexes were obtained from the folding of r $\beta$ <sub>2m</sub> and H-2K<sup>b</sup>cys in the presence of VSV peptide as previously described (21). After purification by gel filtration (G-75, Pharmacia), H-2K<sup>b</sup>/ $\beta$ <sub>2m</sub>/VSV complexes were treated with 1-biotinamido-4-(4'-(maleimidomethyl)-cyclohexanecarboxamido)-butane (Pierce, Rockford, IL), a biotinylation reagent specific for free -SH groups. This procedure ensures the incorporation of biotin only at the free cysteine residue engineered at the C terminus of H-2K<sup>b</sup>. Tetramerization of the biotinylated H-2K<sup>b</sup>/VSV complexes was obtained by incubation with streptavidin-PE at a molar ratio equal to 8:1, ensuring the saturation of the four biotin-binding sites of streptavidin. H-2K<sup>b</sup>/VSV tetramers were purified from the excess of H-2K<sup>b</sup>/VSV monomers by gel filtration in a G-200 column (Pharmacia).

VSV-specific CD8<sup>+</sup> CTL populations from B6 and N30.7 V $\alpha$ 2 transgenic mice were double stained with 0.5  $\mu$ g of H-2K<sup>b</sup>/VSV tetramers-PE and 0.5  $\mu$ g of anti-CD8 $\alpha$ -FITC mAb (PharMingen, San Diego, CA) for 1 h in the presence of 0.1% BSA (fraction V, Sigma, St. Louis, MO). Cells were washed three times with 0.1% PBS-BSA and immediately analyzed using FACScan (Becton Dickinson, Mountain View, CA). Splenocytes from naive B6 and N30.7 V $\alpha$ 2 transgenic mice were included as controls in all of these experiments.


### Flow cytometric analysis of TCR V $\beta$ usage in peptide-specific CD8<sup>+</sup> CTL populations

At day 14 of culture,  $1 \times 10^5$  cells from the peptide-specific CTL populations were double stained for CD8 $\alpha$  and for TCR V $\beta$  with a panel of FITC-conjugated Abs specific for different TCR V $\beta$  families. Those Abs included: anti-V $\beta$ 2 (B20.6), anti-V $\beta$ 4 (KT4), anti-V $\beta$ 5 (MR9-4), anti-V $\beta$ 6 (RR4-7), anti-V $\beta$ 7 (TR310), anti-V $\beta$ 8.1/8.2 (MR5-2), anti-V $\beta$ 8.3 (1B3.3), anti-V $\beta$ 9 (MR10-2), anti-V $\beta$ 10 (B21.5), anti-V $\beta$ 11 (RR3-15), anti-V $\beta$ 12 (MR11-1), anti-V $\beta$ 13 (MR12-3), and anti-V $\beta$ 14 (14-2). All of the Abs

Peptide name	TCR			TCR			TCR	
	1	2	3	4	5	6	7	8
VSV	R	G	Y	V	Y	Q	G	L
K1	K	-	-	-	-	-	-	-
I1	I	-	-	-	-	-	-	-
K6	-	-	-	-	-	K	-	-
R6	-	-	-	-	-	R	-	-
E6	-	-	-	-	-	E	-	-
D6	-	-	-	-	-	D	-	-
I6	-	-	-	-	-	I	-	-
M6	-	-	-	-	-	M	-	-

**FIGURE 1.** Sequence of VSV and peptide variants used for immunization. For peptide variants, only residues different from those of the VSV peptide are shown. "TCR" indicates the TCR-contact residues of the VSV peptide.

**FIGURE 2.** All of the peptide variants trigger an equivalent cytotoxicity response in immunized B6 (A) and N30.7 V $\alpha$ 2 transgenic mice (B). Mice were immunized by injection of 15  $\mu$ g peptide emulsified in CFA in the hind footpads and were boosted 7 days later with 15  $\mu$ g peptide emulsified in IFA. One week after the booster, splenocytes were cultured in the presence of IL-2 and the same peptide used for immunization. After 14 days of culture, cytotoxicity was determined by  $^{51}$ Cr release from peptide-loaded RMA/s cells using 1  $\mu$ M peptide and an E:T ratio of 40.



were purchased from PharMingen. Cells were incubated for 30 min on ice with 0.1  $\mu$ g of anti-CD8 $\alpha$ -PE and 0.1  $\mu$ g of the specific anti-V $\beta$  mAb in the presence of 0.1% BSA (fraction V, Sigma). After incubations, cells were washed three times with 0.1% PBS-BSA and immediately analyzed using FACScan (Becton Dickinson). Data are reported as the fraction of total CD8 $^{+}$  cells expressing a particular V $\beta$  family. Statistical analyses were performed using the Student *t* test.

## Results

*Immunization of B6 mice with the VSV peptide triggers a CD8 $^{+}$  T cell-mediated cytotoxic response biased to the relative contribution of a few TCR V $\beta$  elements*

It has been previously observed that mice mount a cytotoxic immune response after immunization with peptides of the proper length and sequence for MHC class I binding (25, 26). In this study, immunization of B6 mice with the VSV peptide (Fig. 1), which binds to H-2K $^{b}$ , triggered a strong peptide-specific cytotoxic response (Fig. 2A). The responding CD8 $^{+}$  CTL populations were strongly biased to the participation of T cells that showed the preferential usage of the V $\beta$ 13 and V $\beta$ 8.1/8.2 (8.1 or 8.2) elements (Table I). These V $\beta$  families represented up to 50% of the total CD8 $^{+}$  CTL population, with the V $\beta$ 13 gene element being always predominant and significantly expanded as compared with unimmunized mice ( $p < 0.001$ ) (Table I). No significant expansion of any of the other V $\beta$  families tested was consistently observed after immunization with VSV peptide (Table I).

To evaluate the Ag specificity of the entire CD8 $^{+}$  T cell population responding to the VSV peptide, tetramers of the H-2K $^{b}$ /VSV complex were utilized for binding to CD8 $^{+}$  T cells. MHC/peptide tetramers are extremely sensitive reagents for the detection of peptide-specific T cells (27). As shown in Fig. 3B, the majority of CD8 $^{+}$  T cells responding to VSV peptide bound to H-2K $^{b}$ /VSV tetramers, indicating that this MHC/peptide complex is the specific ligand for those CD8 $^{+}$  lymphocytes. As control, splenocytes ob-

tained from naive B6 mice were also stained with H-2K $^{b}$ /VSV tetramers and anti-CD8 mAb; however, CD8 $^{+}$  T cells from these naive animals did not bind H-2K $^{b}$ /VSV tetramers (Fig. 3A).

*Single amino acid replacements toward the C terminus of the VSV peptide cause an alteration in the TCR V $\beta$  repertoire of the responding peptide-specific CD8 $^{+}$  CTL populations in B6 mice*

The H-2K $^{b}$ /VSV crystal structure shows that positions 1 (N terminus) and 6 (toward the C terminus) of the VSV peptide are solvent exposed and available to contact the TCR (21, 22). Functional studies from our laboratory have suggested proximity between the TCR  $\beta$ -chain and position 6 of the VSV peptide (24, 28). We therefore evaluated whether single amino acid replacements at position 6 of the VSV peptide could alter the TCR V $\beta$  repertoire of the responding CD8 $^{+}$  CTL populations.

Like the VSV peptide, VSV-derived peptide variants carrying single substitutions at position 6 (Fig. 1) were able to elicit cytotoxic responses in B6 mice (Fig. 2A). However, the TCR V $\beta$  usage of the CD8 $^{+}$  T cells expanded by immunization with position 6 peptide variants was significantly altered compared with the V $\beta$  usage of anti-VSV CTL populations. For example, in the case of the M6 peptide, in which the glutamine residue at position 6 was replaced by methionine, CD8 $^{+}$  CTL populations were induced that showed a usage of V $\beta$ 13 similar to those induced by VSV, but M6 also induced abundant V $\beta$ 11 $^{+}$  CD8 $^{+}$  T cells (Fig. 4A). The V $\beta$ 11 element was expressed by 20% of the M6-induced CTLs, a frequency significantly higher than the 6% of V $\beta$ 11 $^{+}$  cells present in the VSV-induced CTL populations ( $p < 0.0001$ ).


Furthermore, a peptide variant carrying lysine in place of glutamine at position 6 (K6) induced CD8 $^{+}$  CTL populations that preferentially used V $\beta$ 8.1/8.2 (Fig. 4A). The V $\beta$ 8.1/8.2 usage of these cells (24%) was significantly higher than that observed in VSV-specific CD8 $^{+}$  T cells ( $p < 0.0086$ ). The V $\beta$ 13 element was

Table I. Immunization with VSV peptide induces the expansion of CD8 $^{+}$  T cells that express a restricted set of TCR V $\beta$  elements in B6 and N30.7 V $\alpha$ 2 transgenic mice<sup>a</sup>

	V $\beta$ 2	V $\beta$ 4	V $\beta$ 5	V $\beta$ 6	V $\beta$ 7	V $\beta$ 8.1/2	V $\beta$ 8.3	V $\beta$ 9	V $\beta$ 10	V $\beta$ 11	V $\beta$ 12	V $\beta$ 13	V $\beta$ 14
B6 naive	2.2	10.4	3.5	6.0	3.6	14.3	8.8	7.1	9.5	6.6	6.8	4.6	0.7
B6 VSV immune	1.8	5.9	7.9	2.6	8.5	20.1**	6.7	4.2	4.9	5.9	1.6	29.1*	6.6
N30.7 V $\alpha$ 2 Tg naive	2.0	9.1	5.7	6.1	6.5	13.5	6.9	3.7	3.6	5.3	5.2	3.3	3.3
N30.7 V $\alpha$ 2 Tg VSV immune	1.7	8.2	5.9	3.1	5.2	2.9	2.1	2.0	1.5	1.8	1.3	68.7***	4.5

<sup>a</sup> In B6 mice, immunization with VSV peptide expanded preferentially CD8 $^{+}$  T cells expressing V $\beta$ 13, followed by V $\beta$ 8.1/2 ( $*p < 0.001$  and  $**p < 0.05$ , when compared with nonimmunized mice). On the other hand, in VSV-immunized N30.7 V $\alpha$ 2 transgenic mice, V $\beta$ 13 was the only element significantly expanded in CD8 $^{+}$  T cells ( $***p < 0.005$  when compared with nonimmunized littermates). Mice were immunized by injecting 15  $\mu$ g of VSV peptide emulsified in CFA in the hind footpads and boosted 7 days later with 15  $\mu$ g of VSV peptide in IFA. At 1 wk after the booster, splenocytes were cultured in the presence of IL-2 and the same peptide used for immunization. After 14 days of culture, TCR V $\beta$  usage was analyzed by flow cytometry using a panel of TCR V $\beta$ -specific Abs. Data are expressed as percentage of CD8 $^{+}$  T cells that express a particular V $\beta$  element. Each number represents the average of three independent experiments.

**FIGURE 3.** CD8<sup>+</sup> T cells from VSV peptide-specific CTL populations bind specifically to H-2K<sup>b</sup>/VSV tetramers. CTL populations from B6 (B) and N30.7 V $\alpha$ 2 transgenic (D) mice immunized with VSV peptide were double stained with H-2K<sup>b</sup>/VSV tetramers-PE and anti-CD8 $\alpha$ -FITC and analyzed using FACS. Splenocytes from naive B6 (A) and N30.7 V $\alpha$ 2 transgenic (C) mice were included as controls.



practically absent in K6-specific CTL populations from these mice (5.7% compared with the 25.2% observed in VSV-specific CTLs,  $p < 0.0002$ ).


Two other peptides carrying replacements at position 6 of VSV were used for immunization of B6 mice; these were E6 and I6, in which glutamine 6 was replaced by glutamic acid or isoleucine, respectively. The preferential TCR V $\beta$  usage observed in E6-specific CD8<sup>+</sup> CTL populations was V $\beta$ 8.1/8.2 (14%, Fig. 4A). The V $\beta$ 13 element (7.6%) was significantly reduced when compared with VSV-specific CD8<sup>+</sup> CTLs (25.2%,  $p < 0.005$ ). In the case of I6 peptide-specific CD8<sup>+</sup> CTL populations from B6 mice, the frequency of the V $\beta$ 13 gene element was also decreased (4.3%,  $p < 0.01$ ) (Fig. 4A).

*Single amino acid replacements at the N terminus of the VSV peptide do not alter the TCR V $\beta$  repertoire of the responding peptide-specific CD8<sup>+</sup> CTL populations in B6 mice*

Two replacements were made at position 1 of VSV, where the wild-type arginine residue was either changed to lysine (a conservative change) or isoleucine (a nonconservative change). These K1 and I1 peptide variants (Fig. 1) were able to trigger peptide-specific cytotoxic responses in B6 mice similar to that observed for the VSV wild-type peptide (Fig. 2A). When the TCR V $\beta$  usage was analyzed, the CD8<sup>+</sup> CTL populations specific for these two peptides showed a pattern similar to that observed in VSV-induced CD8<sup>+</sup> CTL populations (Fig. 4B). Thus, the predominant V $\beta$  elements used by K1- or I1-induced CD8<sup>+</sup> CTL populations were V $\beta$ 13 and V $\beta$ 8.1/8.2. In the case of K1-induced CTL populations, there appeared to be a decrease in V $\beta$ 13 usage when compared with VSV-induced CTL populations, but this difference was not statistically significant.


*Immunization of N30.7 V $\alpha$ 2 transgenic mice with VSV peptide triggers a CD8<sup>+</sup> T cell-mediated cytotoxic response biased to the contribution of a single TCR V $\beta$  element*

To focus our study only on the repertoire of TCR  $\beta$ -chains independently of variations in the TCR  $\alpha$ -chain, we created a transgenic mouse expressing the TCR  $\alpha$ -chain of the H-2K<sup>b</sup>/VSV-specific CTL clone N30.7, in an endogenous TCR $\alpha$ -deficient background. T cells obtained from these mice express only the transgenic TCR  $\alpha$ -chain (V $\alpha$ 2, Fig. 5), since they carry a mutation in the endogenous C $\alpha$  gene (24, 29). When N30.7 TCR $\alpha$  transgenic mice were immunized with the VSV peptide, a strong, specific cytotoxic response was obtained



**FIGURE 4.** Only single replacements near the C terminus of VSV peptide alter the TCR V $\beta$  usage in peptide-specific CTL populations derived from B6 mice. Mice were immunized by injection of 15  $\mu$ g peptide emulsified in CFA in the hind footpads and were boosted 7 days later with 15  $\mu$ g peptide emulsified in IFA. One week after the booster, splenocytes were cultured in the presence of IL-2 and the same peptide used for immunization. After 14 days of culture, TCR V $\beta$  usage was determined by flow cytometry using a panel of TCR V $\beta$ -specific Abs. The results are expressed as percentage of CD8<sup>+</sup> T cells that express a particular V $\beta$  gene element. Only the V $\beta$  elements that were expanded upon immunization with each peptide are shown. A, M6 peptide induces the expansion of V $\beta$ 13<sup>+</sup> CD8<sup>+</sup> T cells but also expands V $\beta$ 11<sup>+</sup> CD8<sup>+</sup> T cells (\*\*,  $p < 0.0001$  when compared with VSV peptide). K6, E6, and I6 peptides abolished the predominance of V $\beta$ 13 in peptide-specific CTLs (#,  $p < 0.0002$ ; &,  $p < 0.005$ ; and  $\psi$ ,  $p < 0.001$  when compared with VSV peptide). In K6-specific CTL populations, V $\beta$ 8.1/8.2 was increased as compared with VSV peptide (\*,  $p < 0.0086$ ). B, Peptide variants carrying mutations at P1 (N terminus of VSV) do not significantly alter the TCR V $\beta$  usage of peptide-specific CTL populations. Groups of five mice were immunized with each peptide. Each bar represents the average of three to five independent experiments.

**FIGURE 5.**  $\alpha\beta$  T cells from N30.7  $V\alpha 2$  TCR $\alpha$  transgenic mice carrying a homozygous mutation in their endogenous TCR $\alpha$  locus express only the transgenic TCR  $\alpha$ -chain. Splenocytes obtained from N30.7  $V\alpha 2$  TCR $\alpha$  transgenic mice heterozygous (A) or homozygous (B) for a mutation in the TCR $\alpha$  locus were double stained with the anti-TCR  $\beta$ -chain (H57-FITC) and the anti- $V\alpha 2$  (B20.1-PE) Abs and analyzed by FACS.



(Fig. 2B). In these mice,  $V\beta 13^+$   $CD8^+$  cytotoxic T cells represented up to 70% of the VSV peptide-specific CTL population (Table I and Fig. 6A). Neither  $V\beta 8.1/8.2$  nor any other of the tested  $V\beta$  elements were observed to predominate in VSV-specific CTL populations from these mice (Table I).

Similarly to what was observed with the B6 mice immunized with the VSV peptide, the  $CD8^+$  T cells responding to the VSV peptide from N30.7  $V\alpha 2$  transgenic mice bound H-2K $^b$ /VSV tetramers (Fig. 3D). Thus, those  $CD8^+$  lymphocytes are specific for the H-2K $^b$ /VSV complex. Naive  $CD8^+$  T cells from spleens of unimmunized N30.7  $V\alpha 2$  transgenic mice did not bind H-2K $^b$ /VSV tetramers (Fig. 3C).

*Single amino acid replacements toward the C terminus of VSV peptide cause an alteration in the TCR  $V\beta$  repertoire of the responding peptide-specific  $CD8^+$  CTL populations in N30.7  $V\alpha 2$  transgenic mice*


As was observed in B6 mice, immunization of N30.7  $V\alpha 2$  transgenic mice with peptide variants carrying certain replacements at position 6 of the VSV peptide also resulted in significant alterations of the TCR  $V\beta$  usage. R6-specific  $CD8^+$  CTL populations induced in N30.7  $V\alpha 2$  transgenic mice show two major TCR  $\beta$ -chain families (Fig. 6A):  $V\beta 11$  (48.7%) and  $V\beta 13$  (38.2%). These frequencies differ significantly from those observed in VSV-specific CTL populations ( $V\beta 11$ , 1.8%, and  $V\beta 13$ , 69%;  $p < 0.001$  in each case), indicating that this single amino acid replacement in the peptide favors the expansion of  $V\beta 11^+$  T cells. In contrast, the K6 and I6 peptides maintained  $V\beta 13$  as the major  $V\beta$  element present in the responding  $CD8^+$  CTL populations (Fig. 6A). This result contrasts with the observed reduction in  $V\beta 13$  usage in B6 mice immunized with those peptides (Fig. 4A; see Discussion).

As seen in Fig. 6A, a negative charge in position 6 of the VSV peptide induced the expansion of  $V\beta 7^+$   $CD8^+$  T cells. Thus, D6 peptide-specific CTL populations show  $V\beta 7$  (27.5%) and  $V\beta 13$  (24.6%) as the two major  $V\beta$  elements involved in D6 recognition. These values differ significantly from VSV-induced CTL populations, in which  $V\beta 7$  is expressed in only 5% of the  $CD8^+$  T cells ( $p < 0.001$ ). Furthermore, E6 peptide-induced  $CD8^+$  CTL populations show  $V\beta 7$  as the only significant  $V\beta$  element (73%), contrasting the low frequency of this  $V\beta$  family in VSV-induced CTL populations (5%,  $p < 0.0001$ ).

*Single amino acid replacements at the N terminus of VSV peptide do not alter the TCR  $V\beta$  repertoire of the responding peptide-specific  $CD8^+$  CTL populations in N30.7  $V\alpha 2$  transgenic mice*

N30.7 TCR $\alpha$  transgenic mice mounted a strong cytotoxic response to the K1 and I1 peptides (Fig. 2B) and showed  $V\beta 13$  as the predominant  $V\beta$  element present in the peptide-specific  $CD8^+$  CTL populations (Fig. 6B). None of the other  $V\beta$  elements tested were significantly abundant in these peptide-specific CTL populations.

Thus, while peptides carrying single substitutions at position 1 of the VSV peptide were able to trigger a cytotoxic immune response in both wild-type B6 and N30.7  $V\alpha 2$  transgenic mice, they did not significantly alter the TCR  $V\beta$  usage in  $CD8^+$  CTL populations expanded after peptide immunization.



**FIGURE 6.** Only single replacements near the C terminus of VSV peptide alter the TCR  $V\beta$  usage in peptide-specific CTL populations derived from N30.7  $V\alpha 2$  transgenic mice. Mice were immunized by injection of 15  $\mu\text{g}$  peptide emulsified in CFA in the hind footpads and were boosted 7 days later with 15  $\mu\text{g}$  peptide emulsified in IFA. One week after the booster, splenocytes were cultured in the presence of IL-2 and the same peptide used for immunization. After 14 days of culture, TCR  $V\beta$  usage was analyzed by flow cytometry using a panel of TCR  $V\beta$ -specific Abs. The results are expressed as percentage of  $CD8^+$  T cells that express a particular  $V\beta$  gene element. Only the  $V\beta$  elements that were expanded upon immunization with each peptide are shown. A, Similarly to VSV, peptide variants K6, R6, and I6 induce the expansion of T cells expressing  $V\beta 13$ . In addition, R6 peptide expanded T cells expressing  $V\beta 11$  TCRs (\*,  $p < 0.001$  when compared with VSV peptide). Peptide variants carrying negative residues at position 6 (E6 and D6) reduced the predominance of  $V\beta 13$  and increased  $V\beta 7$  in peptide-specific CTLs ( $\psi$ ,  $p < 0.0005$ ; \*\*,  $p < 0.002$ ; #,  $p < 0.0021$ ; and \*\*\*,  $p < 0.005$ , when compared with VSV peptide). B, Peptide variants carrying mutations at P1 (N terminus of VSV) do not significantly alter the TCR  $V\beta$  usage of peptide-specific CTL populations. Groups of three mice were immunized with each peptide. Each bar represents the average of two or three independent experiments.

*VSV peptide variants that alter the TCR V $\beta$  repertoire are not recognized by VSV-specific CTL populations*

Since certain VSV peptide variants carrying mutations at position 6 of the VSV peptide abolished the predominance of V $\beta$ 13 in the responding CD8<sup>+</sup> T cell populations, it might be expected that those peptide variants would not be recognized by VSV-specific CTL populations that are enriched in V $\beta$ 13 TCRs. Indeed, VSV-specific CTL populations from B6 mice cross-reacted only with those peptide variants that did not alter the V $\beta$  usage (Table II), namely, K1, I1, and M6 peptides. These three peptides induced an equivalent expansion of V $\beta$ 13<sup>+</sup> CD8<sup>+</sup> T lymphocytes upon immunization as did the wild-type VSV peptide (Fig. 4, A and B). These results support a correlation between TCR V $\beta$  usage and the Ag specificity of CTL populations.

## Discussion

The recently solved TCR/MHC-peptide structures have provided key information about the interactions taking place during Ag recognition, revealing that not only the TCR CDR3 loops, as was initially proposed, but also the germline-encoded CDR1 loops can contribute to the interaction with the antigenic peptide bound to the MHC groove (8–11). Evidence for the occurrence of CDR1-peptide interactions in vivo has not yet been shown. Here we provide in vivo evidence for an active role of the antigenic peptide in the expansion of T cells carrying a restricted set of V $\beta$  elements during a cytotoxic immune response. We observe that single amino acid substitutions in the antigenic peptide can profoundly alter the distribution of V $\beta$  elements on a responding peptide-specific CTL population. Such findings are consistent with the notion that there is an interaction between the germline-encoded CDR $\beta$  loops and the peptide.

It has been reported previously that T cell responses to specific Ags can be biased, as shown by the expansion of a limited number of TCR V $\alpha$  and V $\beta$  elements (15–18). We report here that the H-2K<sup>b</sup>-restricted cytotoxic T cell response to the VSV peptide in B6 mice is mediated mainly by CD8<sup>+</sup> T cells expressing V $\beta$ 13 or V $\beta$ 8.1/8.2 TCR molecules (Table I, Fig. 4A). That H-2K<sup>b</sup>/VSV is the specific ligand for those CD8<sup>+</sup> T cells is demonstrated by the fact that they bind to H-2K<sup>b</sup>/VSV tetramers (Fig. 3). We have also found that single amino acid substitutions at TCR-contact residues of the VSV peptide can alter the TCR V $\beta$  usage of a peptide-specific CTL population. Furthermore, only substitutions near the C terminus of the peptide altered the V $\beta$  usage, a finding consistent

with the notion of an interaction between this region of the peptide and the TCR V $\beta$  domain (Fig. 4A). However, it is possible that the point mutation in the peptide could affect the V $\alpha$  usage in the B6 mice and that the observed alteration in the V $\beta$  usage could be a secondary effect due to V $\alpha$ V $\beta$  pairing restrictions. This could be a feasible alternative, especially in view of previously reported restrictions on the pairing of specific TCR V $\alpha$  and V $\beta$  elements (30–33).

To evaluate whether the effect of the peptide mutation on the TCR V $\beta$  usage is a direct or indirect effect on the  $\beta$ -chain, we fixed the TCR  $\alpha$ -chain as a transgene, allowing the analysis of TCR  $\beta$ -chains independently of the TCR V $\alpha$  usage. With this aim, a transgenic mouse was engineered expressing the TCR  $\alpha$ -chain from a VSV-specific clone (N30.7) in an endogenous C $\alpha$ -deficient background (24, 29). Although these mice express only the transgenic TCR  $\alpha$ -chain and no endogenous  $\alpha$ -chains (Fig. 5), they potentially can express any of the endogenous TCR V $\beta$  elements (Table I). When these mice were immunized with the VSV peptide, only V $\beta$ 13 TCRs were significantly expanded. In agreement with what was observed in the B6 mice, only amino acid replacements near the C terminus of the VSV peptide altered the V $\beta$  usage in peptide-immunized N30.7 V $\alpha$ 2 transgenic mice (Fig. 6A). Since these mice express the transgenic TCR  $\alpha$ -chain in the absence of any endogenous  $\alpha$ -chain, the alterations of the TCR V $\beta$  usage resulting from replacements near the C terminus of VSV peptide are not an indirect effect due to alterations of the TCR  $\alpha$ -chain, but are a direct effect on the TCR  $\beta$ -chain. Such data are consistent with an orientation in which the TCR  $\beta$ -chain is interacting in vivo with the C-terminal region of the VSV peptide; furthermore, since the observed alterations in the TCR V $\beta$  usage affected entire CTL populations, it is highly probable that this TCR/MHC-peptide orientation is common for most of the T cell clones involved in the recognition of K<sup>b</sup>/VSV complex.

Despite the similarities between B6 and TCR $\alpha$  transgenic mice in the response to K<sup>b</sup>/VSV, some important differences were observed after peptide immunization. It is noteworthy that V $\beta$ 8.1/8.2, V $\beta$  elements that were abundant in VSV-specific CTL populations derived from B6 mice, were significantly reduced in VSV-specific CTL populations derived from N30.7 V $\alpha$ 2 transgenic mice. Moreover, in these transgenic mice there was no significant V $\beta$ 8.1/8.2 usage after immunization with any of the peptides tested. In contrast, these TCR V $\beta$  elements were abundant in most of the peptide-specific CTL populations derived from B6 mice and even predominant in the case of the K6 peptide. Furthermore, TCR $\alpha$  transgenic mice responded to K6 and I6 peptides by expanding V $\beta$ 13 TCRs, while B6 mice responded to the same peptides by preferentially expanding V $\beta$ 8.1/8.2 TCRs, with no significant V $\beta$ 13 expansion. These observations could be the result of structural restrictions imposed by the transgenic TCR  $\alpha$ -chain on the universe of V $\beta$  elements with which it can pair to produce a functional TCR $\alpha\beta$  heterodimer able to recognize H-2K<sup>b</sup>/VSV. V $\alpha$ V $\beta$  pairing restrictions have been observed previously in other systems in which structural constraints on TCR formation could limit the association between different TCR V $\alpha$  and V $\beta$  elements (30–33).

The molecular basis for the changes of the TCR V $\beta$  usage in response to small alterations in the antigenic peptide sequence described here is currently unknown. However, one or more of the following three explanations could account for this phenomenon: 1) a direct contact between the CDR1 of the TCR  $\beta$ -chain and position 6 of the VSV peptide, 2) the requirement for particular CDR1 and/or CDR2 structures to position a given CDR3 sequence during recognition of the VSV peptide, or 3) a conformational change in the structure of the TCR binding domain of the MHC due to the single mutation in the peptide.

Table II. VSV-specific CTL populations derived from B6 mice recognize peptide variants that do not alter TCR V $\beta$ 13 usage<sup>a</sup>

Peptide <sup>b</sup>	Specific Lysis <sup>c</sup>	% V $\beta$ 13 <sup>d</sup>
VSV	100.0	25.2
K1	96.0	15.3
I1	98.0	34.0
M6	95.0	21.1
E6	47.0	7.6
K6	22.0	5.7
I6	11.0	4.3

<sup>a</sup> The ability of a VSV-specific CTL population to recognize peptide variants carrying single amino acid replacements at either position 1 or 6 was evaluated. Recognition of each peptide variant was standardized with regard to recognition of VSV peptide (100%). Cytotoxicity was determined by <sup>51</sup>Cr release from peptide-loaded RMA/s cells at 1  $\mu$ M peptide and E:T ratio equal to 40.

<sup>b</sup> Target peptide.

<sup>c</sup> Specific lysis: standardized considering cytotoxicity obtained with VSV peptide as 100%.

<sup>d</sup> Percentage of CD8<sup>+</sup> T cells expressing V $\beta$ 13 in CTL population induced by the target peptide.

The first explanation implies a direct contact between the CDR1 of the TCR  $\beta$ -chain and position 6 of the VSV peptide. Thus, single replacements at that position of the peptide could impose restrictions on the universe of TCR  $V\beta$  elements that would be expanded upon peptide immunization. This hypothesis suggests a role for CDR1 $\beta$  in recognition of the peptide bound to the MHC, a notion supported by the recently reported high-resolution crystal structures of TCRs complexed with their cognate ligands. In both human and mouse systems, the CDR1 of the TCR  $\beta$ -chain interacts with residues toward the C terminus of the antigenic peptide bound to the MHC groove (8–10). In fact, in the 2C/H-2K<sup>b</sup>-dEV8 structure reported by Garcia et al., 2C-CDR1 $\beta$  makes 6 contacts with position 6 of the dEV8 peptide as compared with CDR3 $\beta$ , which makes only one (10). In addition, site-directed mutagenesis studies have provided evidence for a role of CDR1 $\beta$  loops in recognition of MHC class I-peptide complexes (34, 35), although those experiments could not determine whether the CDR1 $\beta$  loop was interacting with residues of the peptide or of the MHC. Thus, a direct interaction between the CDR1 $\beta$  loop and the antigenic peptide is a feasible explanation for the changes in  $V\beta$  usage reported here.

Alternatively, the second possibility is that particular CDR1 and CDR2 structures would be required to accommodate or position a CDR3 loop of a specific sequence during Ag recognition. We have recently reported that single replacements in P6 of the VSV peptide induced charge-compensatory changes at position 98 of the TCR CDR3 $\beta$  loop (CDR3 $\beta$ 98) (24). While negatively charged residues at P6 expanded TCRs with a positive charge at CDR3 $\beta$ 98, the opposite finding was observed with positively charged residues at P6 of VSV (24). This requirement for certain CDR3 sequences could limit the germline-encoded CDR1 and CDR2 loop structures that would allow Ag recognition. Further support for this view comes from the observation that in hybridomas recognizing MHC class II-peptide complexes, the use of a particular  $V\beta$  gene segment correlated with the presence of a given CDR3 $\beta$  sequence motif (36).

Finally, the third explanation suggests that a single change in the peptide sequence could induce a conformational change in the MHC structure that would alter its binding domain for TCRs. Such an alteration could then be responsible for the expansion of CTLs carrying TCRs with different variable gene elements. To explore this possibility for the E6 peptide, which most profoundly alters  $V\beta$  usage in the TCR  $\alpha$ -chain transgenic mice (Fig. 6A), we have recently solved the structure for the H-2K<sup>b</sup>/E6-peptide complex and compared it with the H-2K<sup>b</sup>/VSV structure (C. T. Thomson, A. M. Kalergis, S. G. Nathenson, and J. C. Sacchettini, manuscript in preparation). The only conformational changes observed between these two MHC-peptide complexes were localized to the peptide. Therefore, in the case of the E6 peptide, the alteration in  $V\beta$  usage is not due to conformational changes in MHC residues. However, in two previous crystallographic studies, peptide variants carrying single substitutions at TCR-contact residues were observed to induce changes in the conformation of at least one MHC residue (37, 38). These two studies raise the possibility that for peptides other than E6, conformational changes in MHC residues could be involved in causing the changes in the TCR  $V\beta$  gene usage observed as a result of single substitutions at position 6 of the VSV peptide.

When considered together with previous observations made in MHC class II-restricted responses (36, 39, 40), our results reveal that alterations in the TCR repertoire of the responding T cell population due to minor changes in the Ag are a general and biologically significant phenomenon affecting both CD4<sup>+</sup> and CD8<sup>+</sup> compartments. Previous studies performed in CD4<sup>+</sup> T cell-mediated responses specific for antigenic peptides bound to MHC class

II molecules have shown that replacements at positions toward the C terminus of the peptide can alter the TCR  $V\beta$  usage of the responding CD4<sup>+</sup> T cells (36, 39, 40). By studying entire peptide-specific CD8<sup>+</sup> cytotoxic T cell populations, we have observed that replacements at TCR-contact residues of the antigenic peptide can alter the TCR repertoire, supporting the notion that this is a common feature shared by both MHC class I- and II-restricted immune responses.

We demonstrate here that cytotoxic immune responses are particularly sensitive to minor epitope alterations. It is striking that only a single replacement in a TCR-contact residue of the VSV peptide can completely modify the TCR repertoire of the responding CTL population. In addition, those peptide variants that altered the TCR repertoire are not recognized by VSV-wild-type peptide-specific CTL populations. Such a phenomenon could be relevant for understanding the strategies used by pathogens to evade the immune system. It is well known that antigenic variation is a common strategy employed by a number of different microorganisms, including viruses, bacteria, and protozoans to escape recognition by immune cells (41). Our findings show that a change in a single amino acid residue of an immunodominant T cell epitope would require the host organism to generate an entirely new immune T cell response.

## Acknowledgements

We thank Drs. Matthew Scharff, Betty Diamond, and Anne Davidson, as well as Andrew Sikora and Matt Roden, for critical reading of the manuscript. We also thank David Gebhard at the FACS facility for technical assistance, Edith Palmieri for folding and purification of H-2K<sup>b</sup>/VSV, and Marie Muranelli for secretarial assistance.

## References

- Berke, G. 1994. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. *Annu. Rev. Immunol.* 12:735.
- Zimmerman, C., K. Brduscha-Riem, C. Blaser, R. M. Zinkernagel, and H. Pircher. 1996. Visualization, characterization and turnover of CD8<sup>+</sup> memory T cells in virus-infected hosts. *J. Exp. Med.* 183:1367.
- Joyce, S., and S. G. Nathenson. 1996. Alloreactivity, antigen recognition and T cell selection: three diverse T cell recognition problems with a common solution. *Immunol. Rev.* 154:59.
- Chien, Y. H., and M. M. Davis. 1993. How  $\alpha\beta$  T-cell receptors "see" peptide/MHC complexes. *Immunol. Today* 14:597.
- Bentley, G. A., and R. A. Mariuzza. 1996. The structure of the T cell antigen receptor. *Annu. Rev. Immunol.* 14:563.
- Arden, B. 1998. Conserved motifs in T-cell receptor CDR1 and CDR2: implications for ligand and CD8 co-receptor binding. *Curr. Opin. Immunol.* 10:74.
- Eisen, H. N., Y. Sykulev, and T. J. Tsomides. 1996. Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. *Adv. Protein Chem.* 49:1.
- Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. *Nature* 384:134.
- Garcia, K. C., M. Degano, R. L. Stanfield, A. Brunmark, M. R. Jackson, P. A. Peterson, L. Teyton, and I. A. Wilson. 1996. An  $\alpha\beta$  TCR structure at 2.5 Å and its orientation in the TCR-MHC complex. *Science* 274:209.
- Garcia, K. C., M. Degano, L. R. Pease, M. Huang, P. A. Peterson, L. Teyton, and I. A. Wilson. 1998. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. *Science* 279:1166.
- Ding, Y. H., K. J. Smith, D. N. Garboczi, U. Utz, W. E. Biddison, and D. C. Wiley. 1998. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. *Immunity* 8:403.
- Teng, M. K., A. Smolyar, A. G. Tse, J. H. Liu, J. Liu, R. E. Hussey, S. G. Nathenson, H. C. Chang, E. L. Reinherz, and J. H. Wang. 1998. Identification of a common docking topology with substantial variation among different TCR-peptide-MHC complexes. *Curr. Biol.* 8:409.
- Sun, R., S. Shepherd, S. S. Geier, C. T. Thomson, J. M. Sheil, and S. G. Nathenson. 1995. Evidence that the antigen receptors of cytotoxic T lymphocytes interact with a common recognition pattern on the H-2K<sup>b</sup> molecule. *Immunity* 3:573.
- Sant'Angelo, D. B., G. Waterbury, P. Preston-Hurlburt, S. T. Yoon, R. Medzhitov, S. C. Hong, and C. A. Janeway, Jr. 1996. The specificity and orientation of a TCR to its peptide-MHC class II ligands. *Immunity* 4:367.

15. Cose, S. C., J. M. Kelly, and F. R. Carbone. 1995. Characterization of a diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential V $\beta$  bias. *J. Virol.* 69:5849.
16. Aruga, A., E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak, and A. E. Chang. 1997. Type 1 versus type 2 cytokine release by V $\beta$  T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. *J. Immunol.* 159:664.
17. Maryanski, J. L., C. V. Jongeneel, P. Bucher, J. L. Casanova, and P. R. Walker. 1996. Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. *Immunity* 4:47.
18. Pannetier, C., J. Even, and P. Kourilsky. 1995. T-cell repertoire diversity and clonal expansions in normal and clinical samples. *Immunol. Today* 16:176.
19. Van Bleek, G. M., and S. G. Nathenson. 1990. Isolation of an endogenously processed immunodominant viral peptide from class I H-2 K<sup>b</sup> molecule. *Nature* 348:213.
20. Imarai, M., E. C. Goyarts, G. M. van Bleek, and S. G. Nathenson. 1995. Diversity of T cell receptors specific for the VSV antigenic peptide (N52-59) bound by the H-2K<sup>b</sup> class I molecule. *Cell. Immunol.* 160:33.
21. Zhang, W., A. C. Young, M. Imarai, S. G. Nathenson, and J. C. Sacchettini. 1992. Crystal structure of the major histocompatibility complex class I H-2K<sup>b</sup> molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. *Proc. Natl. Acad. Sci. USA* 89:8403.
22. Fremont, D. H., M. Matsumura, E. A. Stura, P. A. Peterson, and I. A. Wilson. 1992. Crystal structures of two viral peptides in complex with murine MHC class I H-2 K<sup>b</sup>. *Science* 257:919.
23. Shibata, K. I., M. Imarai, G. M. van Bleek, S. Joyce, and S. G. Nathenson. 1992. Vesicular stomatitis virus antigenic octapeptide N52-59 is anchored into the groove of the H-2K<sup>b</sup> molecule by the side chains of three amino acids and the main-chain atoms of the amino terminus. *Proc. Natl. Acad. Sci. USA* 89:3135.
24. Wang, F., T. Ono, A. M. Kalergis, W. Zhang, T. P. DiLorenzo, K. Lim, and S. G. Nathenson. 1998. On defining the rules for interaction between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor  $\beta$  chain. *Proc. Natl. Acad. Sci. USA* 95:5217.
25. Sakita, I., H. Horig, R. Sun, F. Wang, and S. G. Nathenson. 1996. In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complexes. *J. Immunol. Methods* 192:105.
26. Fayolle, C., U. M. Abdel-Motal, L. Berg, E. Deriaud, M. Jondal, and C. Leclerc. 1996. Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4<sup>+</sup> T-cell help. *Immunology* 89:41.
27. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. *Science* 274:94.
28. Ono, T., T. P. DiLorenzo, F. Wang, A. M. Kalergis, and S. G. Nathenson. 1998. Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants. *J. Immunol.* 161:5454.
29. Mombaerts, P., A. R. Clarke, M. A. Rudnicki, J. Iacomini, S. Itohara, J. J. Lafaille, L. Wang, Y. Ichikawa, R. Jaenisch, M. L. Hooper, and S. Tonegawa. 1992. Mutations in T-cell antigen receptor genes  $\alpha$  and  $\beta$  block thymocyte development at different stages. *Nature* 360:225.
30. Burns, R. P. Jr., K. Natarajan, N. J. LoCascio, D. P. O'Brien, J. A. Kobori, N. Shastri, and R. K. Barth. 1998. Molecular analysis of skewed TCR  $\alpha$ -V gene usage in T-cell receptor  $\beta$ -chain transgenic mice. *Immunogenetics* 47:107.
31. Malissen, M., J. Trucy, F. Letourneur, N. Rebai, D. E. Dunn, F. W. Fitch, L. Hood, and B. Malissen. 1988. A T cell clone expresses two T cell receptor  $\alpha$  genes but uses one  $\alpha\beta$  heterodimer for allorecognition and self MHC-restricted antigen recognition. *Cell* 55:49.
32. Saito, T., J. L. Sussman, J. D. Ashwell, and R. N. Germain. 1989. Marked differences in the efficiency of expression of distinct  $\alpha\beta$  T cell receptor heterodimers. *J. Immunol.* 143:3379.
33. Vacchio, M. S., L. Granger, O. Kanagawa, B. Malissen, K. Tomonari, S. O. Sharrow, and R. J. Hodes. 1993. T cell receptor V $\alpha$ -V $\beta$  combinatorial selection in the expressed T cell repertoire. *J. Immunol.* 151:1322.
34. Lone, Y. C., M. Bellio, A. Prochnicka-Chalufour, D. M. Ojcius, N. Boissel, T. H. Ottenhoff, R. D. Klausner, J. P. Abastado, and P. Kourilsky. 1994. Role of the CDR1 region of the TCR  $\beta$  chain in the binding to purified MHC-peptide complex. *Int. Immunol.* 6:1561.
35. Bellio, M., Y. C. Lone, O. de la Calle-Martin, B. Malissen, J. P. Abastado, and P. Kourilsky. 1994. The V $\beta$  complementarity determining region 1 of a major histocompatibility complex (MHC) class I-restricted T cell receptor is involved in the recognition of peptide/MHC I and superantigen/MHC II complex. *J. Exp. Med.* 179:1087.
36. Jorgensen, J. L., U. Esser, B. de St. Groth, P. Reay, and M. M. Davis. 1992. Mapping T cell receptor-peptide contacts by variant peptide immunization of single chain transgenics. *Nature* 355:224.
37. Reid, S. W., S. McAdam, K. J. Smith, P. Klenerman, C. A. O'Callaghan, K. Harlos, B. K. Jakobsen, A. J. McMichael, J. I. Bell, D. I. Stuart, and E. Y. Jones. 1996. Antagonist HIV-1 gag peptides induce structural changes in HLA B8. *J. Exp. Med.* 184:2279.
38. Ghendler, Y., M. K. Teng, J. H. Liu, T. Witte, J. Liu, K. S. Kim, P. Kern, H. C. Chang, J. H. Wang, and E. L. Reinherz. 1998. Differential thymic selection outcomes stimulated by focal structural alteration in peptide/major histocompatibility complex ligands. *Proc. Natl. Acad. Sci. USA* 95:10061.
39. Itoh, Y., K. Kajino, K. Ogasawara, A. Takahashi, K. Namba, I. Negishi, N. Matsuki, K. Iwabuchi, M. Kakinuma, R. Good, and K. Onoe. 1997. Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-A<sup>b</sup> molecule. *Proc. Natl. Acad. Sci. USA* 94:12047.
40. Carson, R. T., K. M. Vignali, D. L. Woodland, and D. A. Vignali. 1997. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. *Immunity* 7:387.
41. McMichael, A. 1998. T cell responses and viral escape. *Cell* 93:673.